Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-15
2011-03-15
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
07906480
ABSTRACT:
The invention features methods for the treatment of vaginal atrophy by administering a parathyroid hormone peptide or peptide analog and formulations thereof.
REFERENCES:
patent: 4086196 (1978-04-01), Tregear
patent: 4423037 (1983-12-01), Rosenblatt et al.
patent: 4771124 (1988-09-01), Rosenblatt et al.
patent: 4833125 (1989-05-01), Neer et al.
patent: 4968669 (1990-11-01), Rosenblatt et al.
patent: 5001223 (1991-03-01), Rosenblatt et al.
patent: 5087562 (1992-02-01), Rosenblatt et al.
patent: 5093233 (1992-03-01), Rosenblatt et al.
patent: 5116952 (1992-05-01), Martin et al.
patent: 5149779 (1992-09-01), Chorev et al.
patent: 5171670 (1992-12-01), Kronenberg et al.
patent: 5229489 (1993-07-01), Kanmera et al.
patent: 5260065 (1993-11-01), Mathur et al.
patent: 5317010 (1994-05-01), Pang et al.
patent: 5382658 (1995-01-01), Kronis et al.
patent: 5393869 (1995-02-01), Nakagawa et al.
patent: 5434246 (1995-07-01), Fukuda et al.
patent: 5461064 (1995-10-01), Cullinan
patent: 5527772 (1996-06-01), Holick
patent: 5589452 (1996-12-01), Krstenansky et al.
patent: 5807823 (1998-09-01), Krstenansky et al.
patent: 5821255 (1998-10-01), Roger et al.
patent: 5840690 (1998-11-01), Holick
patent: 5977070 (1999-11-01), Piazza et al.
patent: 6025467 (2000-02-01), Fukuda et al.
patent: 6060077 (2000-05-01), Meignant
patent: 6066618 (2000-05-01), Holick
patent: 6190691 (2001-02-01), Mak
patent: 6190693 (2001-02-01), Kafrissen et al.
patent: 6306914 (2001-10-01), de Ziegler et al.
patent: 6355670 (2002-03-01), Maclean et al.
patent: 6362163 (2002-03-01), Gardella et al.
patent: 2004/0013719 (2004-01-01), Holick
patent: 0 477 885 (1992-04-01), None
patent: WO 94/02510 (1994-02-01), None
patent: WO 00/23594 (2000-04-01), None
patent: WO 00/31137 (2000-06-01), None
patent: WO 02/28420 (2002-04-01), None
Andersson et al., “Intrauterine release of levonorgestrel—A new way of adding progestogen in hormone replacement therapy,”Obstetrics and Gynecology79(6):963-967 (1992).
Clemens et al., “Parathyroid hormone-related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets,”British Journal of Pharmacology134(6):1113-1136 (2001).
Doppelt et al., “Inhibition of the in vivo parathyroid hormone-mediated calcemic response in rats by a synthetic hormone antagonist,”Proceedings of the National Academy of ScienceUSA 83:7557-7560 (1986).
Goldring et al., “Response to Hormones of Cells Cultured from Human Giant Cell Tumors of Bone,”Journal of Clinical Endocrinology and Metabolism46(3):425-433 (1978).
Holick et al., “A parathyroid hormone antagonist stimulates epidermal proliferation and hair growth in mice,”Proceedings of the National Academy of Science91:8014-8016 (1994).
Keutmann et al., “Rat parathyroid hormone-(1-34) fragment: renal adenylate cyclase activity and receptor binding properties in vitro,”Endocrinology117(3):1230-1234 (1985).
Massfelder et al., “Parathyroid hormone-regulated peptide—a smooth muscle tone and proliferation regulatory protein,”Current Opinion in Nephrology and Hypertension7(1):27-32 (1998).
Nissenson et al., “Endogenous biologically active human parathyroid hormone: measurement by a guanyl nucleotide-amplified renal adenylate cyclase assay,”Journal of Clinical Endocrinology and Metabolism52(5):840-846 (1981).
Nussbaum et al., “Design of Analogues of Parathyroid Hormone: A Conformational Approach,”Journal of Protein Chemistry4(6):391-406 (1985).
Nutt et al., “Removal of partial agonism from parathyroid hormone (PTH)-related protein-(7-34)NH2by substitution of PTH amino acids at positions 10 and 11,”Endocrinology127:491-493 (1990).
Orloff et al., “Further evidence for a novel receptor for amino-terminal parathyroid hormone-related protein on keratinocytes and squamous carcinoma cell lines,”Endocrinology186(7):3016-3023 (1995).
Philbrick et al., “Defining the roles of parathyroid hormone-related protein in normal physiology,”Physiological Reviews76(1):127-173 (1996).
Stumpf, “Pharmacokinetics of estrogen,”Obstetrics and Gynecology75:(4 Suppl):9S-14S (1990).
International Search Report for PCT/US2003/16478, mailed Aug. 24, 2004.
International Preliminary Examination Report for PCT/US2003/16478, completed Sep. 10, 2004.
Supplementary European Search Report for EP 03734177, completed Sep. 24, 2009.
Clark & Elbing LLP
Tate Christopher R.
Teller Roy
LandOfFree
Use of a parathyroid hormone peptide analogs for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a parathyroid hormone peptide analogs for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a parathyroid hormone peptide analogs for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2659290